Silymarin Ameliorates Acrylamide-Induced Hyperlipidemic Cardiomyopathy in Male Rats

Table 2

Effect of silymarin on lipid profile in rats treated with acrylamide.

Experimental groups	TC (mg/dl)	TGs (mg/dl)	HDL-C (mg/dl)	LDL-C (mg/dl)	VLDL-C (mg/dl)
Control	86.20^c ± 0.66	58.80^c ± 1.11	47.20^a ± 0.97	35.40^c ± 0.98	11.08^c ± 0.35
AA	174.60^a ± 1.21	133.40^a ± 0.81	33.20^b ± 0.97	107.20^a ± 0.86	26.12^a ± 1.09
SIL	84.60^c ± 1.03	59.60^c ± 0.75	47.0^a ± 0.95	35.20^c ± 0.49	11.48^c ± 0.43
AA+SIL	102.80^b ± 0.73	85.20^b ± 0.86	35.0^b ± 1.64	56.60^b ± 1.29	17.80^b ± 0.58
One-way ANOVA F ()	2064.68 (<0.001^*)	1529.98 (<0.001^*)	41.52 (<0.001^*)	1278.43 (<0.001^*)	108.31 (<0.001^*)

Data are expressed as the mean ± SE of five rats/group. Means within the same column with different superscript letters are significant. *: Statistically significant at . TC: total cholesterol, TG: triglycerides, HDL-C: high-density lipoprotein cholesterol, LDL-C: low-density lipoprotein cholesterol, and VLDL-C: very-low-density lipoprotein cholesterol.